文献速递临床试验与 GCP流行病学与生物统计

氨甲环酸对急性创伤性脑损伤患者死亡、残疾、血管闭塞事件及其他并发症的影响(CRASH-3):一项随机安慰剂对照试验

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
PubMed 文献 · Lancet · 2019-10-14

CRASH-3是一项在29个国家175家医院开展的随机安慰剂对照试验,纳入12737例创伤性脑损伤患者。在伤后3小时内治疗的患者中,氨甲环酸组头部损伤相关死亡风险为18.5%,安慰剂组为19.8%(RR 0.94,95%CI 0.86-1.02)。预设敏感性分析排除基线GCS评分3分或双侧瞳孔无反应的患者后,氨甲环酸组风险为12.5%,安慰剂组为14.0%(RR 0.89,95%CI 0.80-1.00)。

要点

  • 伤后3小时内给予氨甲环酸可降低轻中度颅脑损伤患者的头部损伤相关死亡风险(RR 0.78,95%CI 0.64-0.95)。
  • 重度颅脑损伤患者中氨甲环酸对头部损伤相关死亡无显著影响(RR 0.99,95%CI 0.91-1.07;异质性检验p=0.030)。
  • 氨甲环酸组与安慰剂组血管闭塞事件风险相似(RR 0.98,95%CI 0.74-1.28),癫痫风险亦相似(RR 1.09,95%CI 0.90-1.33)。

核心结论

  • 结果表明氨甲环酸在创伤性脑损伤患者中是安全的,伤后3小时内治疗可降低头部损伤相关死亡。
  • 患者应在伤后尽快接受治疗。

研究设计与样本

  • 随机、安慰剂对照试验,在29个国家175家医院开展。
  • 纳入成人创伤性脑损伤患者,需在伤后3小时内、GCS评分≤12或CT示颅内出血、无重大颅外出血。
  • 2016年方案修改将入组时间窗从8小时限制为3小时,修改时对试验数据设盲。
  • 按1:1随机分配接受氨甲环酸(负荷剂量1g/10分钟,随后1g/8小时输注)或安慰剂。
  • 主要结局为伤后3小时内治疗患者住院期间28天内头部损伤相关死亡。

主要发现

  • 伤后3小时内治疗患者中,头部损伤相关死亡风险氨甲环酸组18.5% vs 安慰剂组19.8%(855 vs 892例事件;RR 0.94,95%CI 0.86-1.02)。
  • 预设敏感性分析排除基线GCS评分3分或双侧瞳孔无反应患者后,氨甲环酸组12.5% vs 安慰剂组14.0%(485 vs 525例事件;RR 0.89,95%CI 0.80-1.00)。
  • 轻中度颅脑损伤患者中氨甲环酸降低头部损伤相关死亡风险(RR 0.78,95%CI 0.64-0.95),重度颅脑损伤患者中无显著影响(RR 0.99,95%CI 0.91-1.07;异质性检验p=0.030)。
  • 轻中度颅脑损伤患者中早期治疗较晚期治疗更有效(p=0.005),重度颅脑损伤患者中治疗时间无显著影响(p=0.73)。
  • 血管闭塞事件风险氨甲环酸组与安慰剂组相似(RR 0.98,95%CI 0.74-1.28),癫痫风险亦相似(RR 1.09,95%CI 0.90-1.33)。

临床怎么用

  • 作者认为,创伤性脑损伤患者应尽快接受氨甲环酸治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death. We aimed to assess the effects of tranexamic acid in patients with TBI. METHODS: This randomised, placebo-controlled trial was done in 175 hospitals in 29 countries. Adults with TBI who were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding were eligible. The time window for eligibility was originally 8 h but in 2016 the protocol was changed to limit recruitment to patients within 3 h of injury. This change was made blind to the trial data, in response to external evidence suggesting that delayed treatment is unlikely to be effective. We randomly assigned (1:1) patients to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was head injury-related death in hospital within 28 days of injury in patients treated within 3 h of injury. We prespecified a sensitivity analysis that excluded patients with a GCS score of 3 and those with bilateral unreactive pupils at baseline. All analyses were done by intention to treat. This trial was registered with ISRCTN (ISRCTN15088122), ClinicalTrials.gov (NCT01402882), EudraCT (2011-003669-14), and the Pan African Clinical Trial Registry (PACTR20121000441277). RESULTS: Between July 20, 2012, and Jan 31, 2019, we randomly allocated 12 737 patients with TBI to receive tranexamic acid (6406 [50·3%] or placebo [6331 [49·7%], of whom 9202 (72·2%) patients were treated within 3 h of injury. Among patients treated within 3 h of injury, the risk of head injury-related death was 18·5% in the tranexamic acid group versus 19·8% in the placebo group (855 vs 892 events; risk ratio [RR] 0·94 [95% CI 0·86-1·02]). In the prespecified sensitivity analysis that excluded patients with a GCS score of 3 or bilateral unreactive pupils at baseline, the risk of head injury-related death was 12·5% in the tranexamic acid group versus 14·0% in the placebo group (485 vs 525 events; RR 0·89 [95% CI 0·80-1·00]). The risk of head injury-related death reduced with tranexamic acid in patients with mild-to-moderate head injury (RR 0·78 [95% CI 0·64-0·95]) but not in patients with severe head injury (0·99 [95% CI 0·91-1·07]; p value for heterogeneity 0·030). Early treatment was more effective than was later treatment in patients with mild and moderate head injury (p=0·005) but time to treatment had no obvious effect in patients with severe head injury (p=0·73). The risk of vascular occlusive events was similar in the tranexamic acid and placebo groups (RR 0·98 (0·74-1·28). The risk of seizures was also similar between groups (1·09 [95% CI 0·90-1·33]). INTERPRETATION: Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of injury reduces head injury-related death. Patients should be treated as soon as possible after injury. FUNDING: National Institute for Health Research Health Technology Assessment, JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and Wellcome Trust (Joint Global Health Trials scheme). TRANSLATIONS: For the Arabic, Chinese, French, Hindi, Japanese, Spanish and Urdu translations of the abstract see Supplementary Material.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019. PMID: 31623894. doi:10.1016/S0140-6736(19)32233-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。